Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? (Q38121600)

29 August 2017

title

Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? (English)

1 reference

29 August 2017

0 references

0 references

Patrick Schrauwen

0 references

Matthijs Hesselink

series ordinal

object named as

Matthijs K C Hesselink

0 references

Silvie Timmers

series ordinal

object named as

Silvie Timmers

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 July 2013

1 reference

Annals of the New York Academy of Sciences

29 August 2017

published in

1 reference

29 August 2017

volume

1290

1 reference

29 August 2017

page(s)

83-89

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Resveratrol improves health and survival of mice on a high-calorie diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Calorie restriction increases muscle mitochondrial biogenesis in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

The role of sirtuins in the control of metabolic homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Pilot study of resveratrol in older adults with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

Resveratrol bioavailability and toxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12185

21 January 2018

Identifiers

DOI

10.1111/NYAS.12185

1 reference

29 August 2017

1 reference